This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.
Oncology Newco will be established as an independent organisation and will be led by bluebird bio’s current chief executive officer Nick Leschly. ... It will also retain research and development responsibilities for bluebird’s oncology pipeline of
This isn't just the CDCN's fight or my fight. It's Our Fight. ... The disorder is just as serious and life-threatening as many rare blood cancers, including progressive non-Hodgkin’s lymphoma.
Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and three solid tumours – colorectal, ovarian and bladder cancer. ... Magrolimab complements our existing work in haematology, adding a non-cell
New ‘chemotherapy-free’ treatment for patients with limited options. Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication ... lymphoma.
MCL is an aggressive type of non-Hodgkin’s lymphoma, and although it responds well to initial treatment, it eventually stops responding and the cancer cells continue to multiply. ... Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene
Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide). ... Biosimilar and generic medicines also had a wildly favourable turn
More from news
Approximately 15 fully matching, plus 126 partially matching documents found.
Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Previously worked in oncology for Allos, Cephalon and AstraZeneca. Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...